Breaking News

Almac Expands Asia Pacific Ops

By Kristin Brooks | March 11, 2014

Establishes centers in Singapore and Japan

Almac has expanded its clinical services and technologies capabilities with regional hubs in Singapore and Japan to provide leadership, as well as technical, project and operational resources in Asia. The company is also establishing a new secondary packaging facility in Singapore to supply management and support drug pooling strategies aimed at optimizing the supply chain, which will open by the end of the year.  
  
Almac’s local teams support studies of various sizes and complexity and services are augmented by a web-based interface to monitor trial execution globally, with multi-lingual technical and project teams, and an in-house 24/7 hotline connecting site staff to on-call clinicians and unblinding specialists. According to the company, by positioning operational resources within the same time zones where trials are executed, Almac is able to resolve issues in less than 24 hours to eliminate communication delays and improve patient care.

Alan Armstrong, chief executive officer of Almac, said, “With 15% of all clinical trials conducted in Asia, it’s imperative that we provide localized service and support to our clients. We’ve long managed clinical trials on a global basis, but there’s now sufficient critical mass that requires we establish dedicated resources in the region. I’m pleased that our international expertise and global capabilities are now even more accessible to sponsors in this critically-important part of the world, and look forward to opening our new packaging facility later this year.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important